Statin therapy following percutaneous coronary revascularisation: time to make LIPS stick?

Br J Cardiol (Acute Interv Cardiol) 2004;11:AIC 38–AIC 40 Leave a comment
Click any image to enlarge
Authors:

The success of the 3-hydroxy-3-methylglutaryl-coenzyme
A reductase inhibitors (statins) in ameliorating
atherothrombotic events is firmly established. Large
randomised controlled clinical trials have consistently (and
unequivocally) demonstrated a beneficial role in reducing
coronary events and total mortality in patients with advanced
coronary artery disease (CAD).

Advertisement
Heart failure - BJC Learning programme
For healthcare professionals only

THERE ARE CURRENTLY NO COMMENTS FOR THIS ARTICLE - LEAVE A COMMENT